Snapshot CAH (Cardinal Health) Backlog Trend Deep Value
NYQ · Healthcare · Medical Distribution
$232.65
-2.24 (-0.95%)
CAH Interactive Price Chart & Trading Signals
CAH Stock Snapshot — Valuation, Risk & Technical Signals
CAH Key Fundamentals, Analyst Targets & Company Profile
Key Financial Ratios
Capitalisation
$54.11B
P/E
32.45
Forward P/E
16.53
PEG
1.17
P/B
-18.80
EPS
$7.17
Rendement dividende
0.88%
52 sem.
$145.87 – $258.30
Beta
0.52
Volume
1.7M
ROE
—
Marge bénéficiaire
0.7%
Croissance CA
5.8%
Marge brute
3.8%
EV/EBITDA
14.00
Objectif analystes
$270.94
The trailing price-to-earnings ratio stands at 32.4x. Forward P/E of 16.5x implies earnings expansion expected. EV/EBITDA sits at 14.00x. Market capitalization is $54.11B. Revenue is growing at 5.8% on a trailing basis. Earnings are expanding at 68.8%. Profit margins are 0.7%. Beta of 0.52 indicates defensive profile.
Analyst Consensus
Recommandation
none
Objectif bas
$235.00
Objectif moyen
$270.94
Objectif haut
$292.00
Basé sur 16 analystes
À propos de Cardinal Health
Cardinal Health, Inc. operates as a healthcare services and products company in the United States and internationally. It operates in two segments: Pharmaceutical and Specialty Solutions, and Global Medical Products and Distribution. The company offers customized solutions for hospitals, healthcare systems, pharmacies, ambulatory surgery centers, clinical laboratories, physician offices, and patients in the home. It distributes branded and generic pharmaceutical, specialty pharmaceutical, and over-the-counter healthcare and consumer products. The company also provides services to pharmaceutical manufacturers and healthcare providers for specialty pharmaceutical products; pharmacy management services to hospitals; operates pharmacies, including pharmacies in community health centers; and repackages generic pharmaceuticals and over-the-counter healthcare products. In addition, it manufactures, sources, and distributes Cardinal Health branded medical, surgical, and laboratory products and devices that include exam and surgical gloves; needles, syringe, and sharps disposals; compression, incontinence, nutritional delivery, and wound care products; single-use surgical drapes, gowns, and apparel products; fluid suction and collection systems; urology products; operating room supply products; and electrode product lines. Further, the company distributes a range of national brand products, including medical, surgical, and laboratory products; provides supply chain services and solutions to hospitals, ambulatory surgery centers, clinical laboratories, and other healthcare providers; and assembles and sells sterile and non-sterile procedure kits. Additionally, it manufactures, prepares, and delivers radiopharmaceuticals; and optimizes direct shipments through integrated technology solutions. The company was incorporated in 1979 and is headquartered in Dublin, Ohio.
CAH Deep Dive Analysis
Bottom Line
Verdict
OvervaluedBest for
General investorWatch out for
Premium valuationData confidence
HighCardinal Health, Inc. (CAH) trades above our multi-model fair value estimate of $194.77 by approximately 16.3%. Trailing P/E: 32.4x. Profitability signals include profit margin of 0.7%. Recent growth metrics show revenue growth of 5.8% and earnings growth of 68.8%. Risk profile: defensive beta of 0.52. Consensus: none.
CAH Deep Dive Analysis
Valuation
Overvalued
P/E 32.4x
Price is above what fundamentals suggest.
Growth
Expanding
Rev 5.8%
Revenue is outpacing the market.
Risk
Low
Beta 0.52
Movement is likely to track the broader market.
Valuation Snapshot
Cardinal Health, Inc. (CAH) trades above our multi-model fair value estimate of $194.77 by approximately 16.3%. The trailing price-to-earnings ratio stands at 32.4x. Forward P/E of 16.5x suggests earnings compression ahead. Price-to-sales is 0.2x. EV/EBITDA sits at 14.0x. Market capitalization is $54.11B.
Why it matters: Paying a premium works only if the company keeps growing faster than expected.
Growth & Profitability
Revenue is growing at 5.8% on a trailing basis. Earnings are expanding at 68.8%. Profit margins are 0.7%. Return on assets is 3.7%.
Why it matters: Growing revenue with healthy margins usually means the business is gaining market share or pricing power.
Risk Profile
Beta of 0.52 indicates defensive profile. Net debt position is $5.14B.
Why it matters: Lower risk means steadier returns, but often with less upside in bull markets.
Analyst Context
Analyst consensus target of $270.94 implies 16.5% upside. Target range spans $235.00 to $292.00. 16 analysts cover the stock. Consensus recommendation: none.
Why it matters: Analyst targets reflect what professionals expect over 12 months. A wide gap between price and target can mean the market disagrees with the consensus.
Investor Fit
Free cash flow yield of 8.4% is attractive for cash-flow-focused investors.
Takeaway: Match the stock's risk-reward profile with your own goals and time horizon. No single metric tells the whole story.
Data Methodology & Sources
Market Data (Facts)
- Price, volume, market cap: Yahoo Finance (delayed ~5 min)
- P/E, EPS, revenue, debt: Yahoo Finance fundamentals
- Analyst targets: Yahoo Finance consensus (may lag)
- Insider trades: SEC EDGAR Form 4 filings
QuantSoar Model (Derived)
- Fair Value: 7-model consensus (DCF, Graham, P/E, P/S, DDM, EV/EBITDA, Div Yield) — trimmed inverse-variance weighted
- Margin of Safety = (Fair Value − Live Price) / Live Price × 100
- Composite Score: 40% Value + 30% Momentum + 30% Risk
- Verdict Gauge: Base 50 + Valuation(±25) + Whale(±10) + Macro(±10) + Technical(±10). Analyst consensus shown separately.
Model outputs are estimates based on available data and are not investment advice. Cross-check with primary sources before making investment decisions.
CAH Overvalued
Cardinal Health, Inc. (CAH) trades above our multi-model fair value estimate of $194.77 by approximately 16.3%.
Frequently Asked Questions
ValuationIs CAH stock overvalued right now?
ValuationWhat is CAH fair value based on current fundamentals?
RiskHow risky is CAH compared with other stocks?
GrowthIs CAH still growing?
AnalystWhat do analysts think about CAH?
DividendDoes CAH pay a dividend?
CatalystWhat could change the investment case for CAH?
Related Stocks
เกี่ยวกับผู้เขียน
Phasakorn Traklang (Peach) — ผู้ก่อตั้ง
ภาสกร ตรากลาง (พีช) เป็นผู้ก่อตั้ง QuantSoar และนักวิจัยการลงทุนเชิงปริมาณที่เชี่ยวชาญด้านการประเมินมูลค่าหุ้นหลายโมเดล การวิเคราะห์กระแสสถาบัน และการสร้างพอร์ตแบบเป็นระบบ เขาสร้างแพลตฟอร์มการเงินที่ขับเคลื่อนด้วยข้อมูลเพื่อให้บริการนักลงทุนรายย่อยทั่วโลก
เชื่อมต่อ LinkedInInvestment Disclaimer: QuantSoar is for informational purposes only. We do not provide personalized investment advice. Always conduct your own research or consult a financial advisor. SEC
Données: Yahoo Finance / SEC EDGAR / Alpha Vantage / Finnhub